The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease.

ABSTRACT: Biomarkers and disease-modifying therapies are both urgent unmet medical needs in the treatment of Parkinson's disease (PD) and must be developed concurrently because of their interdependent relationship: biomarkers for the early detection of disease (i.e., prior to overt neurodegeneration) are necessary in order for patients to receive maximal therapeutic benefit and vice versa; disease-modifying therapies must become available for patients whose potential for disease diagnosis and prognosis can be predicted with biomarkers. This review provides an overview of the milestones achieved to date in the therapeutic strategy development of disease-modifying therapies and biomarkers for PD, with a focus on the most common and advanced genetically linked targets alpha-synuclein (SNCA), leucine-ri

SUBMITTER: Polissidis A 

PROVIDER: S-EPMC7355671 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature